New Delhi: Healthcare Global Enterprises announced the execution of definitive agreements for the business combination of its unit Triesta Sciences with bioinformatics firm Strand Life Sciences Pvt Ltd.
The combination of Triesta and Strand creates an integrated platform with end-to-end capabilities in precision medicine, Healthcare Global Enterprises (HCG) said in a filing to BSE.
Strand, a spin-off from the Indian Institute of Science, is the leader in genomic testing for cancer and inherited diseases in India, the filing said.
“Together we are well on the path to building Asia’s leading integrated analytics-driven diagnostic and genomics research company. Through this alliance, we will work together to be at the forefront of precision medicine,” Strand Founder and CEO Ramesh Hariharan said.